Cns Pharmaceuticals, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Ikarian Capital, LLC and Neil Shahrestani have filed a Schedule 13G, reporting beneficial ownership of 9.9% of CNS Pharmaceuticals, Inc. common stock.
NASDAQ
Stonepine Capital Management has filed a Schedule 13G reporting a 9.9% beneficial ownership stake in CNS Pharmaceuticals, Inc. consisting of common stock and warrants.
NASDAQ
Ikarian Capital, LLC and Neil Shahrestani have filed a Schedule 13G reporting a 5.7% beneficial ownership stake in CNS Pharmaceuticals, Inc.
NASDAQ
Stonepine Capital Management and affiliates report a 7.9% beneficial ownership stake in CNS Pharmaceuticals, Inc. as of December 31, 2025.
NASDAQ
Armistice Capital, LLC and Steven Boyd have disclosed a 4.99% beneficial ownership stake in CNS Pharmaceuticals Inc. common stock.
NASDAQ
Stonepine Capital Management and its affiliates have reported a 5.6% beneficial ownership stake in CNS Pharmaceuticals, Inc. as of October 29, 2025.
NASDAQ
Armistice Capital, LLC and Steven Boyd have disclosed a 9.99% beneficial ownership stake in CNS Pharmaceuticals Inc. common stock.